Pharmaceutical manufacturers are entering a phase in which AI will no longer be an experimental productivity tool used by a few early adopters. It is becoming a practical work capability for quality, manufacturing, engineering, laboratory, training, and regulatory teams. The challenge is not whether AI can summarize documents, draft investigations, analyze trends, or support inspection...
Regulatory inspections by the US Food and Drug Administration (US FDA) and other global authorities require pharmaceutical manufacturers to demonstrate sustained compliance with 21 CFR Parts 210/211, ICH Q7, EU GMP Annex 1, and related regulatory frameworks. Traditional inspection readiness models are reactive, labor-intensive, and dependent on significant manual documentation review and...
Regulatory inspections place pharmaceutical quality and operations teams under intense scrutiny. Following the exit meeting, the issuance of observations triggers a demanding 15-day timeline (for US FDA Inspections) to deliver a complete and defensible response, frequently accompanied by significant stress, coordination challenges, and compliance risk.
